Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Alpha2-Plasmin Inhibitor Deficiency Clinical Presentation

  • Author: Olga Kozyreva, MD; Chief Editor: Perumal Thiagarajan, MD  more...
 
Updated: Oct 21, 2015
 

History

In patients with severe alpha 2-plasmin inhibitor deficiency (alpha 2-PI deficiency, a2-PI deficiency), bleeding patterns are similar to those seen in patients with hemophilia, as follows:

  • Delayed onset of bleeding after minor trauma
  • Prolonged bleeding from cuts and wounds, including mucosal bleeding
  • Increased bruising and hematomas, including muscle bleeding
  • Bleeding into joints following trauma rather than spontaneous joint bleeding
  • Excessive postsurgical bleeding (may be a clue in milder cases)
  • Excessive bruising
  • Increased bleeding following ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs)
Next

Physical

Physical findings in individuals with alpha 2-plasmin inhibitor deficiency (alpha 2-PI deficiency, a2-PI deficiency) depend on the site of bleeding, as follows:

  • Joint bleeds resulting in pain, swelling, and limitation of joint movement (Acute and chronic arthropathy similar to arthropathy seen in patients with severe hemophilia can develop because of chronic joint bleeds.)
  • Epistaxis and other mucosal bleeding
  • Gastrointestinal tract bleeding
  • CNS bleeding
  • Menorrhagia starting at menarche
Previous
Next

Causes

Family studies in the few cases reported thus far suggest that alpha 2-plasmin inhibitor deficiency (alpha 2-PI deficiency, a2-PI deficiency) is inherited as an autosomal recessive trait.

Inherited reductions or inherited functional deficiencies of alpha 2-plasmin inhibitor

Inherited reductions or inherited functional deficiencies of alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) are due to specific defects in the gene coding for alpha 2-plasmin inhibitor, which is located on chromosome 17. The full genomic sequence and the functional implications of all its regions are not currently fully known. The molecular defect has been characterized in a few families. Note the following:

  • In a family with severe deficiency, a trinucleotide deletion led to the synthesis of a dysfunctional protein, which was retained within the cell.
  • In another family, trinucleotide duplication led to production of a dysfunctional protein that could not inhibit plasmin.
  • In a third family, a single base insertion in a codon near the 3' end was the molecular basis for the transcription of an abnormal protein, which had abnormal intracellular transport leading to a plasma deficiency.
  • One specific polymorphism has been found in several white and Japanese persons and will help in the search for future defects.

Acquired causes of alpha 2-plasmin inhibitor deficiency

Acquired causes of alpha 2-plasmin inhibitor deficiency (alpha 2-PI deficiency, a2-PI deficiency) reflect the frequency of the associated disease state. Specific clinical conditions that lead to a reduction in the level of alpha 2-plasmin inhibitor are as follows:

Neonates

Alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) levels in ill neonates are lower than the reference range levels found in healthy full-term neonates and are similar to adult levels. However, the level of the plasmin-alpha 2-PI complex was increased in both healthy and ill neonates, with levels higher than those seen in adults.

Pregnancy

Increased levels of alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) contribute to inhibition of fibrinolysis during pregnancy. However, recognizing the significant role played by plasminogen activator inhibitor type 2 in dampening fibrinolysis is important. Plasminogen activator inhibitor type 2 is produced in increasing amounts by the placenta as the pregnancy advances.

In a study involving women in labor, t-PA levels increased starting early in labor and remained high after placental separation. However, after placental separation, an increase in plasmin–alpha 2-PI complex levels occurred together with an increase in fibrinopeptide A and thrombin-antithrombin complex levels, indicating activation of fibrinolysis before the development of a hypercoagulable state induced by placental separation.

Physiologic examples of increased local fibrinolysis include ovulation and the fluidity of menstrual blood loss. Patients with menorrhagia may have excessive local fibrinolysis and may benefit from antifibrinolytic therapy, but no relationship to reduced levels of alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) has been proven in these patients.

Liver disease

The liver plays a central role in hemostasis. Synthesis of alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) and other physiologically important inhibitors of hemostasis, synthesis of procoagulant, and clearance of activated coagulation factors are regulated by the liver. Severe liver disease is associated with reductions in alpha 2-plasmin inhibitor levels, and the reduction is probably a contributing factor in the well-recognized excessive fibrinolytic activity seen in some patients with liver disease.

Due to decreased synthesis of inhibitors, including alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI), and a decreased ability to clear activated coagulation factors, patients undergoing orthotopic liver transplantation have excess fibrinolytic activity, particularly during the anhepatic phase, which contributes to increased bleeding.

Systemic thrombolytic therapy

Patients receiving activators of fibrinolysis, such as t-PA or streptokinase, for the treatment of acute myocardial infarction or for extensive venous thromboembolic disease develop a systemic fibrinogenolytic state, with excess plasmin generation resulting from the use of pharmacologic doses of the activators.[4, 6, 7, 8] Reduced alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) levels are common after the use of these agents, with a greater reduction after streptokinase than after t-PA administration.

The increased incidence of bleeding into the CNS in older patients and of large hematomas at invasive sites are the result of excess plasmin, which degrades all recent thrombi and cannot distinguish between a physiologic hemostatic plug and a pathologic thrombus.

Bleeding after cardiopulmonary bypass surgery

Reduced alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) levels with reduced fibrinogen levels, increased fibrin split products, and higher levels of plasminogen activator inhibitor type 1 were found in mediastinal blood that was shed by patients who had again undergone exploratory surgery for excessive bleeding following open heart surgery and who had negative intraoperative findings. The high local fibrinolytic activity with reduction of alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) levels was believed to be secondary to clot formation in the chest; irrigation and removal of the clots along with the use of inhibitors of fibrinolysis help reduce excess local fibrinolytic activity in the chest cavity

In a study, patients undergoing bypass surgery for coronary artery disease were evaluated prospectively, with the study group receiving aprotinin priming of the pump and an intravenous (IV) infusion during bypass surgery.[9] Alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) levels were reduced in the control group, with a marked increase in fibrin split-product and plasmin–alpha 2-PI complex levels, indicating fibrinolysis activation secondary to coagulation activation. Aprotinin treatment effectively suppressed hyperfibrinolysis and reduced postoperative blood loss.[9]

Primary fibrinolysis during supraceliac aortic clamping

Excessive fibrinolysis was found within 20 minutes of clamping in patients undergoing supraceliac aortic clamping but not in patients undergoing infrarenal aortic clamping. Laboratory tests revealed the presence of a primary fibrinolytic state, as evidenced by a reduction in euglobulin lysis times (measure of total fibrinolytic activity in the absence of physiologic inhibitors within the testing system), increased t-PA levels, elevated ratios of t-PA to plasminogen activator inhibitor type 1, and reduced levels of alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI). The supraceliac aortic clamping caused hepatocellular injury with prolonged circulation of t-PA, leading to a profibrinolytic state characterized by an excess generation of plasmin with alpha 2-plasmin inhibitor depletion.

Lung cancer

Increased fibrinolytic activity of lung cancers has been documented over many years. In a series from Japan, 70 patients with both nonsmall cell and small cell lung cancer were studied. Increased levels of plasmin–alpha 2-PI complex had prognostic significance and predicted poor survival independent of other factors, such as histologic findings, age, sex, and presence of metastatic disease, compared with control subjects.

Other studies of patients with lung cancer confirmed the presence of increased levels of plasmin–alpha 2-PI complex, although they found a correlation between higher values of alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) and histologic findings and/or the extent of disease. Plasmin–alpha 2-PI complex might be useful as a marker to predict outcomes in patients with malignancies.

Arterial disease and atherosclerosis

One group of patients with intermittent claudication and another group with coronary artery spasm were found to have increased levels of plasmin–alpha 2-PI complex. In addition, the group with intermittent claudication had higher thrombomodulin levels, whereas the coronary artery spasm group had high levels of thrombin-antithrombin complex. The complex is a sign of activation of coagulation and fibrinolysis secondary to vascular injury.

Fibrinolytic parameters after severe trauma

In a prospective study of the fibrinolytic system in patients admitted with severe trauma, patients had a reduced level of alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) at admission, with increased levels of t-PA antigen and plasminogen activator inhibitor activity.

Enhanced fibrinolysis during hemodialysis

In a study of patients undergoing regular hemodialysis, plasminogen and alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) levels were reduced, with increased levels of plasmin–alpha 2-PI complex present before hemodialysis. Serial sampling during a hemodialysis session showed a continuous fall in alpha 2-plasmin inhibitor levels, with rising levels of plasmin–alpha 2-PI complex at the end of hemodialysis.

t-PA activity and antigen levels rose concomitantly, but plasminogen activator inhibitor type 1 antigen levels dropped, without any further rise in the basal level of cross-linked fibrin degradation products. These findings suggest the presence of a hyperfibrinolytic state before hemodialysis, with further increase during hemodialysis.

Acute leukemia

Patients with acute promyelocytic leukemia are treated routinely with heparin for disseminated intravascular coagulation (DIC), but the hemostatic defect may be due to accelerated fibrinolysis resulting from the release of both t-PA and urokinase-type plasmin activator (u-PA) by leukemic cells. Reduced alpha 2-plasmin inhibitor (alpha 2-PI, a2-PI) levels have been used as a criterion to treat these patients with epsilon-aminocaproic acid (EACA; 6-aminohexanoic acid, Amicar) in combination with heparin, with improvement in bleeding and in abnormal laboratory test findings.

Previous
 
 
Contributor Information and Disclosures
Author

Olga Kozyreva, MD Attending Physician, Division of Hematology-Oncology, St Elizabeth's Medical Center; Assistant Professor, Tufts University School of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Rajalaxmi McKenna, MD, FACP Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems

Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

Jeanine Walenga, PhD 

Jeanine Walenga, PhD is a member of the following medical societies: American Society of Hematology, American Association for Clinical Chemistry, American Heart Association, American Society for Clinical Pathology, International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

Sarah K May, MD Consulting Staff, Department of Hematology-Oncology, Caritas Carney Hospital, Commonwealth Hematology-Oncology PC

Disclosure: Nothing to disclose.

Samer A Bleibel, MD Staff Physician, Department of Internal Medicine, Wayne State University School of Medicine, St John's Hospital and Medical Centers

Samer A Bleibel, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Marcel E Conrad, MD Distinguished Professor of Medicine (Retired), University of South Alabama College of Medicine

Marcel E Conrad, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Blood Banks, American Chemical Society, American College of Physicians, American Physiological Society, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Association of Military Surgeons of the US, International Society of Hematology, Society for Experimental Biology and Medicine, SWOG

Disclosure: Partner received none from No financial interests for none.

Chief Editor

Perumal Thiagarajan, MD Professor, Department of Pathology and Medicine, Baylor College of Medicine; Director, Transfusion Medicine and Hematology Laboratory, Michael E DeBakey Veterans Affairs Medical Center

Perumal Thiagarajan, MD is a member of the following medical societies: American College of Physicians, American Society for Clinical Investigation, Association of American Physicians, American Society for Biochemistry and Molecular Biology, American Heart Association, American Society of Hematology, Royal College of Physicians

Disclosure: Nothing to disclose.

Additional Contributors

S Gerald Sandler, MD, FACP, FCAP Professor of Medicine and Pathology, Director, Transfusion Medicine, Department of Laboratory Medicine, Georgetown University Hospital

S Gerald Sandler, MD, FACP, FCAP is a member of the following medical societies: American Association of Blood Banks, College of American Pathologists, International Society of Blood Transfusion

Disclosure: Nothing to disclose.

References
  1. Koie K, Kamiya T, Ogata K, Takamatsu J. Alpha2-plasmin-inhibitor deficiency (Miyasato disease). Lancet. 1978 Dec 23-30. 2(8104-5):1334-6. [Medline].

  2. Kluft C, Vellenga E, Brommer EJ, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood. 1982 Jun. 59(6):1169-80. [Medline]. [Full Text].

  3. Bachmann F. Plasminogen-plasmin enzyme system. Colman RW, Hirsh J, George JN, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 275-320.

  4. Bachmann F. The fibrinolytic system and thrombolytic agents. Bachmann F, ed. Fibrinolytics and Antifibrinolytics. Berlin, Germany: Springer-Verlag; 2001. 3-15.

  5. Francis CW, Marder VJ. Physiologic regulation and pathologic disorders of fibrinolysis. Colman RW, Hirsh J, George JN, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 975-1002.

  6. Castellino FJ, Ploplis VA. Plasminogen and streptokinase. Bachmann F, ed. Fibrinolytics and Antifibrinolytics. Berlin: Springer-Verlag; 2001. 26-56.

  7. Hedner U, Hirsh J, Marder VJ. Therapy with antifibrinolytic agents. Colman RW, Hirsh J, George JN, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 796-813.

  8. Bachmann F. Disorders of fibrinolysis and use of antifibrinolytic agents. Beutler E, Lichtman MA, Coller BS, et al, eds. Williams Hematology. 6th ed. New York, NY: McGraw-Hill; 2001. 1829-40.

  9. Davis R, Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs. 1995 Jun. 49(6):954-83. [Medline].

  10. American Red Cross. PLAS+SD (pooled plasma, solvent-detergent treated) (monograph). 1999.

  11. PLAS+SD (Pooled Plasma, (Human) Solvent Detergent Treated) [package insert]. Washington DC: American Red Cross, VI Technologies, Inc. October 2000.

  12. MediView Express. Recombinant therapy enhances safety and quality of life for hemophilia patients. Paper presented at: 53rd Annual Meeting of the National Hemophilia Foundation. November 16, 2001; Nashville, Tenn.

  13. Rigas B, Hasan I, Rehman R, et al. Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C. Lancet. 2001 Dec 8. 358(9297):1961-2. [Medline].

  14. Azzi A, De Santis R, Morfini M, et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood. 2001 Oct 15. 98(8):2571-3. [Medline]. [Full Text].

  15. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008 May 29. 358(22):2319-31. [Medline]. [Full Text].

  16. Di Bisceglie AM. SEN and sensibility: interactions between newly discovered and other hepatitis viruses?. Lancet. 2001 Dec 8. 358(9297):1925-6. [Medline].

  17. Senior K. New variant CJD fears threaten blood supplies. Lancet. 2001 Jul 28. 358(9278):304. [Medline].

  18. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002 Jan 10. 415(6868):175-9. [Medline].

  19. Favier R, Aoki N, de Moerloose P. Congenital alpha(2)-plasmin inhibitor deficiencies: a review. Br J Haematol. 2001 Jul. 114(1):4-10. [Medline].

  20. Hanss MM, Farcis M, Ffrench PO, de Mazancourt P, Dechavanne M. A splicing donor site point mutation in intron 6 of the plasmin inhibitor (alpha2 antiplasmin) gene with heterozygous deficiency and a bleeding tendency. Blood Coagul Fibrinolysis. 2003 Jan. 14(1):107-11. [Medline].

  21. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood. 1999 Apr 1. 93(7):2274-81. [Medline]. [Full Text].

  22. Maino A, Garagiola I, Artoni A, Al-Humood S, Peyvandi F. A novel mutation of alpha2-plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency. Haemophilia. 2008 Jan. 14(1):166. [Medline].

  23. Mangel WF, Lin BH, Ramakrishnan V. Characterization of an extremely large, ligand-induced conformational change in plasminogen. Science. 1990 Apr 6. 248(4951):69-73. [Medline].

 
Previous
Next
 
The role of alpha2-plasmin inhibitor (alpha2-antiplasmin) in fibrinolysis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.